PMC:7781431 / 36227-36499
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 1098 | 153-163 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
| 1113 | 89-110 | Disease | denotes | inflammatory diseases | MESH:D007249 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T361 | 0-272 | Sentence | denotes | SPMs and soluble epoxide hydrolase inhibitors are currently in clinical trials for other inflammatory diseases and can be quickly converted and used for SARS-CoV-2 management through the removal of cellular debris and inhibition of inflammatory cytokines (Panigrahy et al. |